Stocks · News reference
Guggenheim analyst Yatin Suneja reiterates Stoke Therapeutics (NASDAQ:STOK) with a Buy and maintains $60 price target.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Filed: 2026-09-25 AccNo: 0001193125-26-402820 Size: 137 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, and Biogen Inc. (NASDAQ:BIIB) today announced presentations
Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, and Biogen Inc. (Nasdaq: BIIB) today announced
JP Morgan analyst Jessica Fye reinstates Stoke Therapeutics (NASDAQ:STOK) with a Overweight and announces $40 price target.